These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33977461)

  • 1. Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose-Response Relationship Using Intracellular Pharmacodynamic Modeling (PD
    Donnellan S; Martínez-Rodríguez C; Aljayyoussi G; Biagini GA
    Methods Mol Biol; 2021; 2296():393-408. PubMed ID: 33977461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis.
    Donnellan S; Aljayyoussi G; Moyo E; Ardrey A; Martinez-Rodriguez C; Ward SA; Biagini GA
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery.
    Moynihan PJ; Besra GS
    Microbiology (Reading); 2017 Oct; 163(10):1385-1388. PubMed ID: 28893361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.
    Tanner L; Denti P; Wiesner L; Warner DF
    IUBMB Life; 2018 Sep; 70(9):926-937. PubMed ID: 29934964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Sawicki R; Ginalska G
    Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunometabolism during Mycobacterium tuberculosis Infection.
    Howard NC; Khader SA
    Trends Microbiol; 2020 Oct; 28(10):832-850. PubMed ID: 32409147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Drug Metab Rev; 2018 Nov; 50(4):448-465. PubMed ID: 30343607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis.
    Zhang YJ; Li XJ; Mi KX
    Yi Chuan; 2016 Oct; 38(10):918-927. PubMed ID: 27806933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis.
    Lan Y; Lam JT; Siu GK; Yam WC; Mason AJ; Lam JK
    Tuberculosis (Edinb); 2014 Dec; 94(6):678-89. PubMed ID: 25154927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
    Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
    Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Parish T
    Expert Opin Drug Discov; 2020 Mar; 15(3):349-358. PubMed ID: 31899974
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration.
    Aljayyoussi G; Jenkins VA; Sharma R; Ardrey A; Donnellan S; Ward SA; Biagini GA
    Sci Rep; 2017 Mar; 7(1):502. PubMed ID: 28356552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery.
    Perveen S; Sharma R
    Biochem Pharmacol; 2022 Mar; 197():114906. PubMed ID: 34990594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
    John SF; Aniemeke E; Ha NP; Chong CR; Gu P; Zhou J; Zhang Y; Graviss EA; Liu JO; Olaleye OA
    Tuberculosis (Edinb); 2016 Dec; 101S():S73-S77. PubMed ID: 27856197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L; Hu X; Chai X; Ye Q; Pang J; Li D; Hou T
    Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.